which is known as Doxil in the US and Caelyx in Europe [57] . It is currently approved for the treatment of AIDSrelated Kaposi's sarcoma and recurrent ovarian cancer in North America, Europe, and other countries, and for metastatic breast cancer in Europe. Liposome-encapsulated doxorubicin has been found to significantly improve the therapeutic index of doxorubicin both in preclinical [58] [59] [60] and in clinical studies [61] [62] [63] [64] . An important advantage of PEGylated liposomal doxorubicin is that the heart muscle uptakes much less of it than free doxorubicin [58, 65] .